

REMARKS

An Office Action was mailed in the above-captioned application on April 24, 2006. As of the Office Action, claims 67-94 were pending. Claims 67-73, 76, 80 and 82-94 were withdrawn from consideration. Claims 74, 75, 77-79 and 81 were rejected. This Request for Reconsideration document is submitted in response to said Office Action.

The Rejection under 35 U.S.C. § 102(b)

The Examiner has rejected Claims 74, 75, 77-79 and 81 under 35 U.S.C. 102(b) as being anticipated by Peltz, et al., *J. Immunol.* 141:1891-96 (1988). The Court of Appeals for the Federal Circuit has stated that anticipation requires the presence in a single prior art reference of each and every element of the claimed invention. *Lindemann Maschinenfabrik GMBH v. American Hoist & Derrick Co.*, 730 F.2d 1452, 1458 (Fed. Cir. 1984); *Alco Standard Corp. v. Tennessee Valley Auth.*, 1 U.S.P.Q.2d 1337, 1341 (Fed. Cir. 1986). “There must be no difference between the claimed invention and the reference disclosure, as viewed by a person of ordinary skill in the field of the invention.” *Scripps Clinic v. Genentech Inc.*, 18 U.S.P.Q.2d 1001, 1010 (Fed. Cir. 1991) (citations omitted).

Specifically, the rejection states that the rejected claims are drawn to an isolated polypeptide comprising an extracellular region of a native Fc γ RII receptor and a fusion component, wherein the fusion component is a carbohydrate, the polypeptide is soluble, or in a pharmaceutical diluent. The rejection reasons that Peltz, et al., discloses a secreted protein containing the extracellular domain of Fc γ RII receptor in HEPES-saline, and that sFc γ RII (26kD) is an N-linked carbohydrate.

Applicant respectfully traverses this rejection. The native N-linked carbohydrates of the 23kD and 26kDa forms of sFc γ RII (p. 1895, left hand column, second paragraph), would not be understood by the person skilled in the art as constituting a “fusion component” in the context of the present invention. Peltz, et al., identifies the forms as “sFc γ RII carrying N-linked oligosaccharides at one and both of the two N-linked glycosylation sides *identified in the Fc γ RII cDNA sequence.*” Thus, in the disclosed mammalian cell expression systems, expressed sFc γ RII is *naturally glycosylated unless the cell culture is conducted in the presence of tunicamycin* (p. 1892, left hand column, fourth complete paragraph).

In contrast, we consider that the term “fusion component” would be understood by the person skilled in the art as referring to something that is *foreign* to the “Fc binding component”. The specification, at page 16, lines 25-35, states that augmentation of the Fc binding component “is achieved by adding a peptide, polypeptide or other molecule which is well tolerated in an animal. . . . The other molecules suitable include dextrans, carbohydrates,”

Additionally, reference to Example 6 of the present specification may be made. This example describes the production of a fusion protein comprising the extracellular region of Fc γ RII fused to human serum albumin (HSA). This fusion protein is expressed in *Pichia pastoris* and, as is readily apparent from the example, the Fc γ RII component is produced in a naturally glycosylated form. Page 50, lines 2-11 describes that the molecular weight of the Fc γ RII component varies according to the expression system, and that this is due to differences in glycosylation. Plainly, the person skilled in the art would understand that the “fusion component” in this example is *not* the carbohydrate(s) linked to the Fc γ RII component through the natural glycosylation process, but rather the foreign HSA fusion component at the N-terminal of the Fc γ RII component.

Applicant submits therefore, that Peltz, et al., does not describe an Fc γ RII receptor and a fusion component, wherein the fusion component is a carbohydrate, and therefore does not anticipate Claims 74, 75, 77-79 and 81. Reconsideration is respectfully requested.

The Rejection under 35 U.S.C. § 103(a)

The Examiner has rejected Claims 75 and 79 under 35 U.S.C. § 103(a) as being unpatentable over Peltz, et al., in view of Yeh, et al., *Proc. Natl. Acad. Sci. USA* 89:1904-1908 (1992). The Examiner bears the burden of establishing a *prima facie* case of obviousness (Section 103). In determining obviousness, one must focus on Applicant's invention as a whole. *Symbol Technologies Inc. v. Opticon Inc.*, 19 U.S.P.Q.2d 1241, 1246 (Fed. Cir. 1991). The primary inquiry is:

whether the prior art would have suggested to one of ordinary skill in the art that this process should be carried out and would have had a reasonable likelihood of success Both the suggestion and the expectation of success must be found in the prior art, not in the applicant's disclosure.

In re Dow Chemical, 5 U.S.P.Q.2d 1529, 1531 (Fed. Cir. 1988). Specifically, the rejection reasons that Yeh, et al., teaches that due to certain characteristics of HSA, the “fusion of

bioactive peptides to HSA is a plausible approach toward the design and recovery of secreted therapeutic HSA derivatives". The rejection further asserts that it would have been obvious to "combine the teachings of Peltz, et al., and Yeh, et al., to arrive at the fusion of soluble Fc γ RII linked to HSA as taught by Yeh, et al. with a reasonable expectation of success.

Applicant respectfully traverses this rejection. Yeh, et al., exemplifies the expression of a *single* fusion protein comprising a soluble CD4 receptor polypeptide fused to HSA. As explained below, and with the possible exception of proteins closely related to CD4, the person skilled in the art would not have held any "reasonable expectation of success" in applying the teachings of Yeh, et al., in the fusing an Fc γ RII component (e.g. the soluble extracellular region of Fc γ RII) to HSA, or any other "fusion component", while maintaining the biological activity of that Fc γ RII component. Reasonable expectation of success is assessed from the perspective of the person of ordinary skill in the art. *See Micro Chem., Inc. v. Great Plains Chem. Co.*, 103 F.3d 1538, 1547, 41 U.S.P.Q.2d (BNA) 1238, 1245.

The extracellular region of Fc γ RII is dissimilar to the CD4 receptor investigated by Yeh, et al. The lack of similarity in the extracellular regions Fc γ RII and the CD4 receptor weighs against a reasonable expectation of success. Additionally, in circumstances where a relatively small protein such as the Fc γ RII extracellular region (26/30 kD) is to be expressed as a fusion protein with a large protein such as HSA (67 kD), there is little *a priori* predictability as to whether the biological activity of the Fc γ RII extracellular region will be maintained. This is because there is a likelihood that the HSA fusion component will interfere with the correct folding of the Fc γ RII component and, additionally, a very real possibility that the fusion component could sterically obscure the immunoglobulin-binding site of the Fc γ RII component. Neither Yeh et al., or Peltz et al., provide any information or guidance which would have allowed the person skilled in the art to dismiss these risks and thereby reasonably predict the success of expressing a biologically active Fc γ RII component as a fusion protein comprising a fusion component such as HSA. Furthermore, Yeh, et al., contains only a single example of expression of a fusion protein comprising HSA. Absent any further exemplification of the successful expression of non-CD4 receptor proteins fused to HSA, it is submitted that the person skilled in the art in 1994 (the priority date of the present claims), would have held considerable doubt as to as to the success of such an approach. The person skilled in the art would have viewed the disclosure of Yeh, et al., at best, as an invitation for further experimentation. At

most, the combination of Yeh, et al., and Peltz, et al., make it “obvious to try” to fuse HSA to a non-CD4 receptor protein. It is well settled that “obvious to try” is an improper consideration in an obviousness rejection. *See Hybritech, Inc. v. Monoclonal Antibodies, Inc.*, 231 U.S.P.Q. 81, 91 (Fed. Cir. 1986).

The rejection appears to use hindsight in making the obviousness rejection in that the rejection finds each element of the pending claims in the prior art, and then reasons that it is easy to reassemble these elements into the invention; however “it is impermissible to use the claimed invention as an instruction manual or “template” to piece together the teaching of the prior art so that the claimed invention is rendered obvious.” *In re Fritch*, 972 F.2d 1260, 1266, 23 USPQ2d 1780, 1784 (Fed. Cir. 1992). The invention must be viewed not with the blueprint drawn by the inventor, but in the state of the art that existed at the time.” *Interconnect Planning Corp. v. Feil*, 774 F2d 1132, 1138, 227 USPQ 543,547 (Fed. Cir. 1985).

It was not until the present inventors carried out the experimentation described at Example 6, that they first became aware that the possibility of expressing a biologically active Fc γ RII component as a fusion protein could be successful. The knowledge gained from that experimentation and, particularly, the realization that a large fusion component such as HSA does not destroy the biological activity of the Fc γ RII component, subsequently led the inventors to investigate the expression of an Fc γ RII component with another fusion component, namely the bacterial maltose binding protein (43 kD). As is mentioned at Example 12 of the present specification (see, particularly, page 61, lines 15-22), a fusion protein comprising the extracellular region of Fc γ RII and bacterial maltose binding protein (denoted WMBPrsFcR) was expressed and was biologically active (i.e. the Fc γ RII component retained the ability to bind to immune complexes). Taken together, these results allowed the present inventors to predict that an Fc γ RII component could be successfully expressed as a fusion protein comprising other fusion components such as immunoglobulin, polyethylene glycol and complement receptors, etc. (see the further discussion of other suitable fusion components at, for example, page 52, lines 7-37). Thus, the present inventors (and others) have subsequently expressed a biologically active Fc γ RII component as a fusion protein comprising the functional domain of the human complement regulatory protein CD46 (see the enclosed copy of Lanteri, M.B. et al., *Transplantation*, 69(6):11281136, Mar 2000).

That the inventors were ultimately successful is irrelevant to whether one of ordinary skill in the art, at the time the invention was made, would have reasonably expected success. *See Standard Oil Co. v. American Cyanamid Co.*, 774 F.2d 448, 454; 227 USPQ 293, 297 (Fed. Cir. 1985). Using the inventors' success as evidence that the success would have been expected is an impermissible use of hindsight. *See In re Kotzab*, 217 F.3d 1365, 1369, 55 U.S.P.Q.2D (BNA) 1313, 1316 (Fed. Cir. 2000).

Given that the combined teachings of Peltz, et al., and Yeh, et al., provide no reasonable expectation of success in the provision of the fusion of soluble Fc γ RII linked to HSA, Applicant respectfully submits that the combination of Peltz, et al., and Yeh, et al., cannot render obvious Claim 75 or 79. Reconsideration is respectfully requested.

Applicant believes that the pending claims are in condition for allowance. If it would be helpful to obtain favorable consideration of this case, the Examiner is encouraged to call and discuss this case with the undersigned.

Respectfully submitted,

SHERIDAN ROSS P.C.

By: _____ /Darla G. Yoerg/
Darla G. Yoerg
Registration No. 48,053
1560 Broadway, Suite 1200
Denver, Colorado 80202-5141
(303) 863-9700

Date: July 24, 2006
Enclosure

LWWOnline | LOGIN | eALERTS | REGISTER | CUSTOMER SUPPORT



Transplantation

THE OFFICIAL JOURNAL OF THE TRANSPLANTATION SOCIETY



Home Search Current Issue Archive

March 27, 2000, 69:6 > INHIBITION OF HYPERACUTE TRANSPLANT...

< Previous

ARTICLE LINKS:

[Abstract](#) | [References \(32\)](#) | [View full-size inline images](#)

Transplantation: Volume 69(6) 27 March 2000 pp 1128-1136

INHIBITION OF HYPERACUTE TRANSPLANT REJECTION BY SOLUBLE PROTEINS WITH THE FUNCTIONAL DOMAINS OF CD46 AND Fc_YR_{II}¹ [Immunobiology]

Lanteri, Marc B.2; Powell, Maree S.; Christiansen, Dale3; Li, Yu Qin; Hogarth, P. Mark; Sandrin, Mauro S.; McKenzie, Ian F. C.; Loveland, Bruce E.4

The Austin Research Institute, Studley Road, Heidelberg, Victoria 3084, Australia

² Current address: Department of Immunology, Hammersmith Hospital, DuCane Road, London, W12 0NN, England.

³ Current address: Immunité et Infections Virales, Faculté de Médecine Lyon-Laennec, IVMC -CNRS-UCBL UMR 5537, 69372 Lyon, Cedex 08, France.

Received 7 June 1999.

Accepted 8 October 1999.

⁴ Address correspondence to: Bruce Loveland, The Austin Research Institute, Studley Road, Heidelberg, Victoria 3084, Australia.

¹ Supported by the National Health and Medical Research Council of Australia and an ARI postgraduate research award (ML).

Abstract

Background. Recombinant soluble forms of complement regulatory molecules, including the human complement regulatory protein CD46 (rsCD46), have been shown to inhibit hyperacute transplant rejection (HAR) and protect against complement-mediated inflammatory tissue damage. Similarly, recombinant soluble forms of the immunoglobulin receptor Fc_YR_{II} (rsFc_YR_{II}) can attenuate antibody-mediated inflammatory responses. We have produced and tested the function of novel recombinant chimeric proteins that incorporate the functional domains of both CD46 (membrane cofactor protein, MCP) and the low affinity human IgG receptor Fc_YR_{II} (CD32).

Methods. Two recombinant soluble chimeric proteins (CD46:FcR and FcR:CD46) were designed and produced using a human cell expression system. Their ability to protect cells against complement-mediated lysis (through the CD46 domain) and bind human IgG (through the Fc

Article Outline

- Abstract
- MATERIALS AND METHODS
 - Animals.
 - Cell lines, antibodies, and serum.
 - Construction of chimeric CD46:Fc_YR_{II} and Fc_YR_{II}:CD46 protein.
 - Production and purification of recombinant proteins.
 - Protein assays.
 - Biodistribution in mice.
 - Complement-mediated lysis.
 - Reverse passive arthus reaction in rats.
 - Heart transplant model in mice.
 - Statistical analysis.

receptor domain) was assessed in vitro. They were also tested in vivo in the rat reverse passive Arthus reaction and a murine model of hyperacute cardiac transplant rejection.

Results. In vitro, the functional domains of the chimeric proteins each retained their activity. In vivo, the serum half-life of the recombinant chimeric proteins in mice was more than either rsCD46 or rsFcγRII. In the rat reverse passive Arthus reaction, intradermal injection of each recombinant protein substantially reduced inflammatory skin edema (>50%) and polymorphonuclear neutrophil infiltration (>90%). In the hyperacute rejection model, i.v. treatment with FcR:CD46 prevented complement-mediated rejection, macroscopic bruising, edema, and thrombosis more effectively than rsCD46.

Conclusions. CD46/FcγRII bifunctional proteins have an improved ability to control complement-mediated hyperacute graft rejection and have therapeutic potential in other conditions involving antibody-mediated inflammation.

Inflammatory immune responses that involve complement activation, alone or together with antibody in immune complexes, are central to the innate and cognate immune systems. Activation of complement can result in opsonisation, lysis of cells by the membrane attack complex, chemotaxis, and the activation of inflammatory cells. These responses are primarily beneficial, but they can also cause tissue damage in acute inflammation or as part of disease processes. The hyperacute rejection of vascularized xenotransplants, resulting from the activation of complement by naturally occurring antibodies (1), is a spectacular example of such damage.

The complement cascade is regulated to prevent inappropriate activation on cell plasma membranes and within body fluids by a number of cell surface and soluble proteins. Several recombinant soluble complement regulators, including rsCD46 and rsCR1 (complement receptor type 1, CD35), have been shown to protect tissues against damage in a variety of pathologies, and have potential therapeutic applications (2, 3).

Inflammatory responses can also be mediated through Fcγ receptors (FcR). Immune complexes of IgG antibody bound to antigen can interact, through binding of the immunoglobulin Fc portion, with cell-surface Fcγ receptors on many cells of hematopoietic lineage, including monocytes, macrophages, neutrophils, platelets, dendritic cells, and B lymphocytes, resulting in clearance of the complexes or modulation of the immune response (4). Deposition of immune complexes is associated with several diseases, such as rheumatoid arthritis, glomerulonephritis, and systemic lupus erythematosus (5), and Fcγ receptors have been shown to be important in animal models of immune-complex disease (6, 7). Naturally occurring soluble forms of these molecules may provide physiological inhibition of this arm of the immune response (8). Recombinant soluble FcγRII can inhibit inflammation, presumably by blocking immune complex binding to cell-surface Fc receptors (9).

It is possible that chimeric soluble molecules that can both bind immune-complexes and regulate complement might be more effective than molecules possessing either function alone. To investigate this, novel bifunctional molecules were produced that combine the functional modules of the human complement regulator CD46 with the Fcγ-binding activity of FcγRII.

CD46 [membrane cofactor protein (MCP)] is one of the key human proteins for complement regulation that is expressed on all nucleated cells. It is able to irreversibly inactivate complement early in the activation cascade, through cofactor activity for the degradation of C3b and C4b by the serum protease factor I, and is especially efficient at inhibition of the alternative complement pathway (3, 10). Its short consensus repeat (SCR) modules mediate this activity. Recombinant forms of CD46, expressed as cell surface proteins on

RESULTS

- Purified recombinant chimeric proteins express conformation...
 - CD46 complement regulation is maintained in both chimeric p...
 - Biodistribution of recombinant proteins in mice.
 - Reduction of inflammation in the reverse passive arthus res...
 - Chimeric proteins prevent hyperacute rejection of mouse hea...
- DISCUSSION
 - REFERENCES

Figures/Tables

- Figure 1
- Figure 2
- Figure 3
- Figure 4
- Figure 5
- Figure 6
- Figure 7
- Table 1
- Figure 8

transfected cells (11, 12) in transgenic mice (13-15), or as recombinant soluble proteins (rsCD46) (3, 16) are effective in protecting cells against complement-mediated lysis and inhibit complement-mediated tissue damage *in vivo* by reducing complement deposition. The ability of human CD46 to regulate complement activation using serum complement from different species (including human, pig, rabbit, guinea pig, rat, and mouse) (3, 11, 16) enables its evaluation in a variety of experimental models.

Fc_yRII has a low affinity for monomeric human immunoglobulin ($K_A < 107 \text{ M}^{-1}$) (17). In soluble form it is likely to circulate free *in vivo* rather than bound to circulating IgG, and should thus be available to localize within sites of inflammation. Moreover, human rsFc_yRII can bind immune complexes consisting of either human, rat or mouse IgG (9) and thus can be applied to a variety of experimental models.

Two chimeric proteins were constructed, with different relative orientations of the CD46 and Fc_yRII components, designated CD46:FcR and FcR:CD46. These and several other control recombinant proteins (depicted in Fig. 1) were tested for the presence of conformation-dependent epitopes, for the ability to regulate complement activation and bind IgG *in vitro*, and for the ability to modulate inflammatory immune responses *in vivo*.




Figure 1. Representation of recombinant soluble chimeric proteins. The modular components of rsCD46 are the \square -60 amino acid short consensus repeat (SCR) domains, SCR 1-4, which encompass the C3b and C4b binding and cofactor activity functions, and the serine, threonine, proline-rich (STP) BC sequence that is heavily O-glycosylated. The BC sequence was included in chimeric proteins with CD46 at the C-terminus. The rsFc_yRII protein contains two domains (D1 and D2) that are members of the Ig super-family. Analysis on SDS-PAGE and Western blotting established the approximate molecular weight. The CD46 SCR 1, 2, and 4 modules and the two FcR domains each have a site for N-linked carbohydrate as indicated.

MATERIALS AND METHODS TOP

Animals. TOP

Inbred mice, Gal o/o (18), C57BL/6J, and (CBAxBALB/c)F1 and outbred rats (Sprague Dawley) were bred or held at the Austin Research Institute.

Cell lines, antibodies, and serum. TOP

CHO-K1 (Chinese hamster ovary fibroblasts; ATCC CCL 61), and 293-EBNA (EBNA transduced human embryonal kidney fibroblasts) (Invitrogen, Carlsbad, CA) were grown in DMEM culture medium (CSL, Melbourne, Australia) supplemented with 10% fetal bovine serum (CSL), 20 $\mu\text{g}/\text{ml}$ proline, 14 $\mu\text{g}/\text{ml}$ hypoxanthine, and 3.9 $\mu\text{g}/\text{ml}$ thymidine. Monoclonal antibodies: E4.3 anti-CD46 (SCR1 module; IgG2a) (19), M177 anti-CD46 (SCR2 module; IgG1) (20), 8.26 anti-Fc_yRII (IgG2b), and 8.7 anti-Fc_yRII (IgG1) (21) were immunopurified on protein A-Sepharose. Human serum from a single donor was freshly prepared and held at 4°C for immediate use in the heart transplant model, or was aliquoted and stored at -70°C for cell lysis assays.

Construction of chimeric CD46:Fc_yRII and Fc_yRII:CD46 proteins. TOP

Expression constructs were derived from cDNA templates previously used to generate recombinant soluble proteins: rsCD46(BC) (16) and human rsFc_yRIIa-H131 (21). The splice-overlap-extension polymerase chain reaction (PCR) method was used to generate individual fragments which in the final PCR produced chimeric constructs ready for ligation into the APEX-3 vector (22). The CD46 and Fc_yRII fragments were joined by a 15-bp linker encoding Gly-Gly-Gly-Lys-Gly. PCR primers were designed to anneal to the 5'-coding sequence and designated 3'-ends of each template and to encode the linker sequence, and anneal, respectively, to the 5'- and 3'-ends of the sequences required at the junctions of the functional domains. Primer sequences, 5' to 3', were for FcR:CD46:

P1 (5'-FcR) GAATTCCA ACTATGGAGACCCAAATGTCTCAG: P2 (linker-3'-FcR):

CTCACAGGCACCCCTGCTCCACCTGGACAGTGATGGTCACAGGC: P3 (linker:5'-CD46):
 ACTGTCTTCAAGGTGAGGCAAGGGTGCTGTGAGGAGGCCAACATTG: and for P4 (3'-CD46)
 ACGAATTCTGATTCAAGGCCACTTCTTACAAGG; and for CD46:FcR: P5 (5'-CD46)
 CGGAATTACAGCGTCTTCGCGCGC: P6 (linker:3'-CD46):
 TGGGGAGCACCCCTGGCTCCACCTTAAAGGACTTTGGAACTGG: P7 (linker:5'-FcR):
 CTTAAAGTGGGTG GAGGCAAGGGTGCTCCCCAACAGGCTGTGCTAAC: and P8 (3'-FcR)
 TCGCCCGATTCTAGACTATTGGACAGTGATGGTCAC. Full cDNA sequences are accessible as GenBank
 MS8050 (CD46) (23) and GenBank J03619 (FcγRIIA) (24). All constructs were fully sequenced to ensure
 they were free of errors. The rsCD46:FcR construct consists of the first 6 exons of CD46 (encoding the
 leader peptide and four SCR modules), then the 5 aa linker, and cDNA encoding the two Ig-superfamily
 extracellular domains of FcγRII. For rsFcR:CD46 the order of functional domains is reversed and in addition
 contains CD46 exons 8 to 10, encoding the 46 residue O-glycosylated membrane-proximal sequence
 designated STP-BC at the carboxy terminus. Two other recombinant constructs, encoding rsCD46:EGFP
 and HSA:FcR, were used to make control proteins. The rsCD46:EGFP protein was expressed and purified
 similarly to the bifunctional chimeras, from a cDNA construct provided by S. Russell and O. Yurieff (The
 Austin Research Institute) that encodes the four SCR modules of CD46 followed by the enhanced green
 fluorescent protein sequence (25). HSA:FcR consists of human serum albumin sequence at the amino
 terminus followed by the two FcγRII extracellular domains (Powell M, manuscript in preparation). Figure 1
 shows diagrammatically the structures of the chimeric proteins.

Production and purification of recombinant proteins. TOP

Expression constructs were transfected into 293-EBNA cells and stable clones were selected with 100 µg/ml hygromycin. Production of recombinant CD46 protein was detected by radioimmunoassay (RIA) using anti-CD46 monoclonal antibodies. Supernatants from transfected cells grown in serum-free medium were passed through a CD46 affinity column containing monoclonal antibodies E4.3, eluted with 25 mM diethylamine pH 11.4, dialyzed against phosphate-buffered saline, and concentrated using Centricon tubes (Amicon, Bedford, MA) (16). Affinity columns of heat-aggregated human gammaglobulin were used to purify rsFcγRII and HSA:FcγRII (9). Concentrations were determined by measuring spectroscopic absorbance at 280 nm (26).

Protein assays. TOP

The purified CD46 chimeric proteins were analyzed by one- and two-dimension SDS-polyacrylamide gel electrophoresis (SDS-PAGE), followed by silver staining, or electroblotting to filters and Western blotting with anti-CD46 monoclonal (E4.3) antibody. Radioimmunoassays utilized the anti-CD46 (E4.3) or anti-FcR (8.26) plate-bound monoclonal antibodies to capture protein and iodinated anti-CD46 M177 monoclonal antibody as tracer (9). Standard curves were prepared from purified proteins. A similar protein capture protocol with an ELISA readout used detection by the horse-radish peroxidase (HRP)-conjugated anti-FcR monoclonal antibody 8.7. Binding of recombinant proteins to human IgG1, IgG3, and IgE was measured using a BiACore 2000 (Pharmacia Biosensor AB, Uppsala, Sweden).

Biodistribution in mice. TOP

The chimeric rsCD46:FcR and rsFcR:CD46 proteins were iodinated using the chloramine T method. Mice [12-week-old (CBABALB/c)F1 males and females] were injected i.v. with 600,000 cpm protein (\square 11-15 ng) diluted to 0.2 ml in PBS. Blood samples were taken at measured intervals and mice were killed at specific times to sample tissues, which were weighed immediately, to measure 125-Iodine content.

Complement-mediated lysis. TOP

In a hemolysis assay, washed sheep erythrocytes coated with rabbit anti-sheep Ig were aliquoted (0.10 ml of 1% v/v), mixed with human serum as complement source (to a final concentration of 0.5%) and recombinant protein to a final volume of 0.20 ml, and incubated for 30 min at 37°C. Hemolysis in the supernatants was measured by absorbance at 405 nm. In a cell lysis assay, CHO-K1 cells, 30,000 per replicate wells, were incubated with polyclonal rabbit anti-CHO serum (final dilution 1/100), rabbit or human serum (as complement source), and recombinant proteins, in 0.05 ml for 60 min at 37°C. The reaction was stopped with 0.15 ml cold PBS, and cell viability was counted by aniline blue dye exclusion (3).

Reverse passive arthus reaction in rats.

Anesthetised female rats (120–150 g) received injections i.v. with 0.6 ml of PBS containing 5 mg ovalbumin and 2% w/v Evans Blue dye, shaved along the back and injected intradermally with 0.10 ml of PBS containing 0.5 mg purified rabbit anti-OVA IgG with or without recombinant soluble proteins, or PBS alone. The same dose (58 µg) of each chimeric recombinant protein was given. Mixtures of rsCD46 and rsFcγRII were also tested at two doses; 29 µg of each and 58 µg of each. The rats were killed after 6 hr, and the area of dye leakage at each injection site, representing edema, was measured. Skin samples were dissected, fixed with formalin, and hematoxylin and eosin stained paraffin-block sections were inspected microscopically for edema and cellular infiltration.

Heart transplant model in mice.

Hearts from 8- to 12-week-old C57BL/6 mice were grafted heterotopically into the abdomen of anesthetized 12-week-old Gal o/o recipients, reperfused, and observed continuously until rejection occurred or for 120 min (1). To precipitate rejection, 0.5 ml of freshly prepared human serum (from one donor) was injected slowly into the recipient's inferior vena cava. The recombinant soluble proteins were injected into the inferior vena cava 10 min prior to the serum, as equimolar doses of 4.5 nM, corresponding to 0.25 mg of rsCD46, 0.40 mg of HSA:FcR and FcR:CD46, and 0.35 mg of CD46:EGFP. Because a limited number of Gal o/o mice were available, the CD46:FcR construct was not used. In control experiments, PBS was injected instead of recombinant protein. Experiments were terminated and grafts taken for histology after rejection (the complete loss of contractile activity) or after 90 min.

Statistical analysis.

P values were calculated for continuous variables using Student's *t* test and for proportions by applying a χ^2 test to the relevant 2×2 table.

RESULTS

Purified recombinant chimeric proteins express conformationally dependent epitopes.

Each recombinant protein was tested for homogeneity by SDS-PAGE analysis on single and two-dimensional gels, followed by silver staining. For each, a single predominant protein species was detected with minor bands sometimes observed after overdevelopment, at sizes corresponding to nonglycosylated protein (Fig. 2A). The observed protein sizes were consistent with the predicted full length mature glycosylated proteins as confirmed by Western blotting using several monoclonal and polyclonal antibodies. Thus, rsCD46:FcR was □75 kDa (3 N-glycosylation sites on CD46 plus 2 on FcγRII; see Fig. 1), rsFcγRII:CD46 was □90 kDa (with multiple O-glycosylation sites on the CD46-BC sequence), and rsCD46 was □55 kDa. Staining with the functionally-blocking conformation-dependent monoclonal antibodies E4.3 (Fig. 2B) or M177 (data not shown) to detect CD46, or 8.26 (anti-FcR) (data not shown), indicated that the functional domains of the secreted proteins had retained their native tertiary structure, and the positions of these aligned with the proteins detected by silver staining.




Figure 2. SDS-PAGE analyses of the recombinant proteins. Recombinant proteins were run on non-reducing gels and either silver-stained (A) or electroblotted and probed with anti-CD46 mAb E4.3 (B). Proteins loaded for silver staining had been immunopurified, whereas Western blotting was of 10-µl samples of supernatant from stably transfected cell lines. Molecular weight standards were used to estimate sizes of the recombinant proteins.

RIA and ELISA assays, in which the capture and probe reagents reacted with the different components of the chimeras, were used to further quantitate the recombinant proteins and demonstrate that multiple conformation-dependent and functionally important epitopes were present. Thus, plate-bound anti-FcR mAb 8.26 was used with iodinated-M177 anti-CD46 (Fig. 3) or HRP-conjugated E4.3; and plate-bound anti-CD46 mAb E4.3 was used with anti-FcR HRP-conjugated monoclonal antibody 8.7 (data not shown). These

assays demonstrated that the epitopes were each present on all of the secreted recombinant molecules. Comparison with standard curves gave estimated concentrations of the chimeric proteins accumulating in culture supernatants to approximately 5 µg/ml. BIAcore analysis demonstrated that the FcR component of the recombinant chimeric proteins bound specifically to human IgG1 and IgG3, but not IgE, similar to rsFcγRII (data not shown).




Figure 3. Binding of chimeric rsFcR:CD46 and rsCD46:FcR proteins to conformation-dependent monoclonal antibodies. Immunopurified proteins were analyzed by radioimmunoassay, using plate-bound anti-FcR mAb 8.26 as capture monoclonal antibodies and detection by iodinated-M177 anti-CD46. Concentrations of the recombinant proteins were determined by absorbance. The data show the mean of duplicate samples (\pm SD) and are typical of multiple assays.

CD46 complement regulation is maintained in both chimeric proteins. TOP

Two assays of complement-mediated cell lysis demonstrated that both rsCD46:FcR and rsFcR:CD46 proteins protected cells. Half-maximal lysis of sensitized erythrocytes by 0.5% human serum (C') was achieved with 125 nM rsCD46:FcR and rsFcR:CD46 (□10 µg/ml), and maximal inhibition occurred with >1 µM (□20 µg/ml) of either protein (Fig. 4A). Lysis of CHO-K1 cells (detected by aniline blue dye uptake) required higher human serum (C') concentrations, and higher concentrations of these recombinant proteins were required for inhibition (Fig. 4B). Rabbit serum (C') produced lysis at lower concentrations, and the recombinant proteins were highly effective at protection (Fig. 4C). The rsCD46:EGFP was as effective as the FcR/CD46 chimeras, demonstrating that the C-terminal globular EGFP molecule had no steric effects on CD46 function (Fig. 4C), although rsFcγRII had no protective activity (data not shown). Titration of each CD46-containing recombinant protein generated similar inhibition curves, also demonstrating that the FcR component did not interfere with binding of C3b or cofactor activity mediated by the CD46 SCR modules.





Figure 4. Lysis of erythrocytes and CHO-K1 cells is regulated by the chimeric proteins. Hemolysis of sensitized erythrocytes occurred in the presence of 0.5% human serum and titrated chimeric proteins (A). CHO cell lysis was measured as aniline blue dye uptake into CHO-K1 cells in the presence of 20% human serum with titrated proteins (B), or the presence of 3% rabbit serum at two protein concentrations (5 and 10 µM) (C). The data show the means \pm SD of triplicate wells and are representative of independent experiments.

Biodistribution of recombinant proteins in mice. TOP

The chimeric proteins were rapidly cleared from the blood after i.v. injection (Fig. 5); the estimated alpha-phase half-life for rsFcR:CD46 was 1.3 min, and for rsCD46:FcR was approximately 20 sec. The comparable alpha-phase half-life of rsCD46 has been previously calculated as less than 1 min (3). The initial rapid removal of protein from the circulation was associated with uptake of Iodine-125 into the liver (data not shown), then a gradual release back into the circulation peaking at about 1 hr. Circulating recombinant protein was readily detectable by radioimmunoassay 90 min after injection of 0.25 mg rsCD46 or 0.4 mg rsFcR:CD46, at an approximate concentration of 0.6 µg/ml (data not shown), suggesting that protein remaining after the first few minutes was cleared more slowly.

Figure 5. Blood content and clearance of chimeric proteins after i.v. injection. Blood samples taken from five mice receiving injections with radiolabeled chimeric proteins were weighed, the radioactive content was determined, and



expressed as a mean percentage of the injected dose assuming that the total blood volume was $\square 7\%$ of total body mass.

Reduction of inflammation in the reverse passive arthus response in rats. ^{TOP}

Clearly delineated skin lesions, mean area $\square 250$ mm² (2), developed at the sites of anti-OVA Ig intradermal injection in rats given ovalbumin i.v. (Fig. 6). A significant reduction ($>50\%, P < 0.05$) in the area of edema was seen when the recombinant proteins (58 μ g) were injected into the dermis with antibody and all had similar inhibitory effects. Thus, smaller lesions occurred in the presence of either rsFcR, rsCD46, or the chimeric proteins, and mixing rsFcR with rsCD46 was not more effective (Fig. 6). Microscopic examination of sites injected with anti-OVA Ig alone revealed a generalized and vigorous cellular infiltrate within the dermis, predominantly of polymorphonuclear cells, with perivascular cuffing (Fig. 7, A and B). Injection of recombinant protein or PBS buffer alone resulted in a largely normal histological picture (Fig. 7C). Addition of the recombinant proteins to the anti-OVA Ig caused a markedly reduced infiltrate throughout the injection site (rsFcR:CD46 shown in Fig. 7D) with the number of PMN scored being $<10\%$ of the normal Arthus reaction. Thus, both CD46 and FcYRII modules inhibited the cellular infiltrate induced by immune complexes and complement activation in the Arthus lesions.




Figure 6. Reduction in reverse passive arthus edema mediated by the recombinant proteins. Affected skin sites ($n=5$), stained by i.v. injected Evans Blue dye, were measured and the mean area ($\pm SD$) was calculated. Negative control skin sites were injected with no antibody or recombinant protein (rsCD46) alone; all other sites received anti-OVA antibody with or without recombinant protein.




Figure 7. Reduction in reverse passive arthus cellular infiltrate mediated by the recombinant proteins. Hematoxylin and eosin-stained paraffin embedded skin sections were prepared from skin sites injected with anti-OVA antibody in the absence of recombinant proteins (A, x20; B, x50), and from sites injected with recombinant protein only (rsCD46 in C, x20) or with anti-OVA antibody plus recombinant protein (D, x20) shows the effect of rsFcR:CD46.

Chimeric proteins prevent hyperacute rejection of mouse heart allografts. ^{TOP}

The allotransplantation of mouse hearts provides a sensitive model of vascularized organ grafts that have been subjected to a period of ischemia: the addition of human anti-Gal antibodies and complement is sufficient to cause hyperacute rejection (1). All Gal+ mouse hearts grafted into Gal o/o mice and given 0.5 ml human serum, but no recombinant protein, were hyperacutely rejected (mean time to rejection 35 min; $n=7$) (Table 1). Rejection was manifested macroscopically by graft swelling, cyanosis, and loss of contractile function. Histology revealed vascular occlusion and sporadic disruption of the endothelium but no interstitial

hemorrhage (Fig. 8A). Treatment with HSA:FcR had no effect: all four hearts were rejected with a mean time of 28 min ($P=0.2$ compared with no treatment) (Table 1). Treatment with the bifunctional chimeric protein FcR:CD46 at a dose of 4.5 nM (0.4 mg) completely prevented hyperacute transplant rejection ($n=5$). The macroscopic and microscopic appearances of these grafts, including heartbeat, were normal throughout the 90-min observation period (Fig. 8B). Treatment of five transplants with equimolar doses of rsCD46 gave variable results. Three hearts were rejected (mean time to rejection 33 min) with histological changes typical of HAR, and two hearts survived more than 90 min (when the experiment was terminated). These nonrejected hearts displayed transient macroscopic swelling and cyanosis within the first 30 min after serum injection, although this was not as pronounced as seen in the hearts that progressed to rejection, and histological examination revealed evidence of edema and tissue damage without occlusive thrombosis (Fig. 8C). A final group of transplants was treated with rsCD46:EGFP. None of these grafts were rejected within the 90-min observation period, although three displayed macroscopic swelling and cyanosis and a microscopic appearance similar to Figure 8C.

Table 1. Bloodlead estimates and hypothesized influence of various lead sources on child blood lead levels		Mean	
Source	Estimated blood lead level (µg/dL)	n	SD
Unadjusted	10.0	100	10.0
1990-1994	10.0	30	10.1
1995-1996	10.0	20	10.0
1997-1998	10.0	20	10.0
1999-2000	10.0	20	10.0
2001-2002	10.0	20	10.0
2003-2004	10.0	20	10.0
2005-2006	10.0	20	10.0
2007-2008	10.0	20	10.0
2008-2009	10.0	20	10.0
2009-2010	10.0	20	10.0
2010-2011	10.0	20	10.0
2011-2012	10.0	20	10.0
2012-2013	10.0	20	10.0
2013-2014	10.0	20	10.0
2014-2015	10.0	20	10.0
2015-2016	10.0	20	10.0
2016-2017	10.0	20	10.0
2017-2018	10.0	20	10.0
2018-2019	10.0	20	10.0
2019-2020	10.0	20	10.0
2020-2021	10.0	20	10.0
2021-2022	10.0	20	10.0
2022-2023	10.0	20	10.0
2023-2024	10.0	20	10.0
2024-2025	10.0	20	10.0
2025-2026	10.0	20	10.0
2026-2027	10.0	20	10.0
2027-2028	10.0	20	10.0
2028-2029	10.0	20	10.0
2029-2030	10.0	20	10.0
2030-2031	10.0	20	10.0
2031-2032	10.0	20	10.0
2032-2033	10.0	20	10.0
2033-2034	10.0	20	10.0
2034-2035	10.0	20	10.0
2035-2036	10.0	20	10.0
2036-2037	10.0	20	10.0
2037-2038	10.0	20	10.0
2038-2039	10.0	20	10.0
2039-2040	10.0	20	10.0
2040-2041	10.0	20	10.0
2041-2042	10.0	20	10.0
2042-2043	10.0	20	10.0
2043-2044	10.0	20	10.0
2044-2045	10.0	20	10.0
2045-2046	10.0	20	10.0
2046-2047	10.0	20	10.0
2047-2048	10.0	20	10.0
2048-2049	10.0	20	10.0
2049-2050	10.0	20	10.0
2050-2051	10.0	20	10.0
2051-2052	10.0	20	10.0
2052-2053	10.0	20	10.0
2053-2054	10.0	20	10.0
2054-2055	10.0	20	10.0
2055-2056	10.0	20	10.0
2056-2057	10.0	20	10.0
2057-2058	10.0	20	10.0
2058-2059	10.0	20	10.0
2059-2060	10.0	20	10.0
2060-2061	10.0	20	10.0
2061-2062	10.0	20	10.0
2062-2063	10.0	20	10.0
2063-2064	10.0	20	10.0
2064-2065	10.0	20	10.0
2065-2066	10.0	20	10.0
2066-2067	10.0	20	10.0
2067-2068	10.0	20	10.0
2068-2069	10.0	20	10.0
2069-2070	10.0	20	10.0
2070-2071	10.0	20	10.0
2071-2072	10.0	20	10.0
2072-2073	10.0	20	10.0
2073-2074	10.0	20	10.0
2074-2075	10.0	20	10.0
2075-2076	10.0	20	10.0
2076-2077	10.0	20	10.0
2077-2078	10.0	20	10.0
2078-2079	10.0	20	10.0
2079-2080	10.0	20	10.0
2080-2081	10.0	20	10.0
2081-2082	10.0	20	10.0
2082-2083	10.0	20	10.0
2083-2084	10.0	20	10.0
2084-2085	10.0	20	10.0
2085-2086	10.0	20	10.0
2086-2087	10.0	20	10.0
2087-2088	10.0	20	10.0
2088-2089	10.0	20	10.0
2089-2090	10.0	20	10.0
2090-2091	10.0	20	10.0
2091-2092	10.0	20	10.0
2092-2093	10.0	20	10.0
2093-2094	10.0	20	10.0
2094-2095	10.0	20	10.0
2095-2096	10.0	20	10.0
2096-2097	10.0	20	10.0
2097-2098	10.0	20	10.0
2098-2099	10.0	20	10.0
2099-20100	10.0	20	10.0
20100-20101	10.0	20	10.0
20101-20102	10.0	20	10.0
20102-20103	10.0	20	10.0
20103-20104	10.0	20	10.0
20104-20105	10.0	20	10.0
20105-20106	10.0	20	10.0
20106-20107	10.0	20	10.0
20107-20108	10.0	20	10.0
20108-20109	10.0	20	10.0
20109-20110	10.0	20	10.0
20110-20111	10.0	20	10.0
20111-20112	10.0	20	10.0
20112-20113	10.0	20	10.0
20113-20114	10.0	20	10.0
20114-20115	10.0	20	10.0
20115-20116	10.0	20	10.0
20116-20117	10.0	20	10.0
20117-20118	10.0	20	10.0
20118-20119	10.0	20	10.0
20119-20120	10.0	20	10.0
20120-20121	10.0	20	10.0
20121-20122	10.0	20	10.0
20122-20123	10.0	20	10.0
20123-20124	10.0	20	10.0
20124-20125	10.0	20	10.0
20125-20126	10.0	20	10.0
20126-20127	10.0	20	10.0
20127-20128	10.0	20	10.0
20128-20129	10.0	20	10.0
20129-20130	10.0	20	10.0
20130-20131	10.0	20	10.0
20131-20132	10.0	20	10.0
20132-20133	10.0	20	10.0
20133-20134	10.0	20	10.0
20134-20135	10.0	20	10.0
20135-20136	10.0	20	10.0
20136-20137	10.0	20	10.0
20137-20138	10.0	20	10.0
20138-20139	10.0	20	10.0
20139-20140	10.0	20	10.0
20140-20141	10.0	20	10.0
20141-20142	10.0	20	10.0
20142-20143	10.0	20	10.0
20143-20144	10.0	20	10.0
20144-20145	10.0	20	10.0
20145-20146	10.0	20	10.0
20146-20147	10.0	20	10.0
20147-20148	10.0	20	10.0
20148-20149	10.0	20	10.0
20149-20150	10.0	20	10.0
20150-20151	10.0	20	10.0
20151-20152	10.0	20	10.0
20152-20153	10.0	20	10.0
20153-20154	10.0	20	10.0
20154-20155	10.0	20	10.0
20155-20156	10.0	20	10.0
20156-20157	10.0	20	10.0
20157-20158	10.0	20	10.0
20158-20159	10.0	20	10.0
20159-20160	10.0	20	10.0
20160-20161	10.0	20	10.0
20161-20162	10.0	20	10.0
20162-20163	10.0	20	10.0
20163-20164	10.0	20	10.0
20164-20165	10.0	20	10.0
20165-20166	10.0	20	10.0
20166-20167	10.0	20	10.0
20167-20168	10.0	20	10.0
20168-20169	10.0	20	10.0
20169-20170	10.0	20	10.0
20170-20171	10.0	20	10.0
20171-20172	10.0	20	10.0
20172-20173	10.0	20	10.0
20173-20174	10.0	20	10.0
20174-20175	10.0	20	10.0
20175-20176	10.0	20	10.0
20176-20177	10.0	20	10.0
20177-20178	10.0	20	10.0
20178-20179	10.0	20	10.0
20179-20180	10.0	20	10.0
20180-20181	10.0	20	10.0
20181-20182	10.0	20	10.0
20182-20183	10.0	20	10.0
20183-20184	10.0	20	10.0
20184-20185	10.0	20	10.0
20185-20186	10.0	20	10.0
20186-20187	10.0	20	10.0
20187-20188	10.0	20	10.0
20188-20189	10.0	20	10.0
20189-20190	10.0	20	10.0
20190-20191	10.0	20	10.0
20191-20192	10.0	20	10.0
20192-20193	10.0	20	10.0
20193-20194	10.0	20	10.0
20194-20195	10.0	20	10.0
20195-20196	10.0	20	10.0
20196-20197	10.0	20	10.0
20197-20198	10.0	20	10.0
20198-20199	10.0	20	10.0
20199-20200	10.0	20	10.0
20200-20201	10.0	20	10.0
20201-20202	10.0	20	10.0
20202-20203	10.0	20	10.0
20203-20204	10.0	20	10.0
20204-20205	10.0	20	10.0
20205-20206	10.0	20	10.0
20206-20207	10.0	20	10.0
20207-20208	10.0	20	10.0
20208-20209	10.0	20	10.0
20209-20210	10.0	20	10.0
20210-20211	10.0	20	10.0
20211-20212	10.0	20	10.0
20212-20213	10.0	20	10.0
20213-20214	10.0	20	10.0
20214-20215	10.0	20	10.0
20215-20216	10.0	20	10.0
20216-20217	10.0	20	10.0
20217-20218	10.0	20	10.0
20218-20219	10.0	20	10.0
20219-20220	10.0	20	10.0
20220-20221	10.0	20	10.0
20221-20222	10.0	20	10.0
20222-20223	10.0	20	10.0
20223-20224	10.0	20	10.0
20224-20225	10.0	20	10.0
20225-20226	10.0	20	10.0
20226-20227	10.0	20	10.0
20227-20228	10.0	20	10.0
20228-20229	10.0	20	10.0
20229-20230	10.0	20	10.0
20230-20231	10.0	20	10.0
20231-20232	10.0	20	10.0
20232-20233	10.0	20	10.0
20233-20234	10.0	20	10.0
20234-20235	10.0	20	10.0
20235-20236	10.0	20	10.0
20236-20237	10.0	20	10.0
20237-20238	10.0	20	10.0
20238-20239	10.0	20	10.0
20239-20240	10.0	20	10.0
20240-20241	10.0	20	10.0
20241-20242	10.0	20	10.0
20242-20243	10.0	20	10.0
20243-20244	10.0	20	10.0
20244-20245	10.0	20	10.0
20245-20246	10.0	20	10.0
20246-20247	10.0	20	10.0
20247-20248	10.0	20	10.0
20248-20249	10.0	20	10.0
20249-20250	10.0	20	10.0
20250-20251	10.0	20	10.0
20251-20252	10.0	20	10.0
20252-20253	10.0	20	10.0
20253-20254	10.0	20	10.0
20254-20255	10.0	20	10.0
20255-20256	10.0	20	10.0
20256-20257	10.0	20	10.0
20257-20258	10.0	20	10.0
20258-20259	10.0	20	10.0
20259-20260	10.0	20	10.0
20260-20261	10.0	20	10.0
20261-20262	10.0	20	10.0
20262-20263	10.0	20	10.0
20263-20264	10.0	20	10.0
20264-20265	10.0	20	10.0
20265-20266	10.0	20	10.0
20266-20267	10.0	20	10.0
20267-20268	10.0	20	10.0
20268-20269	10.0	20	10.0
20269-20270	10.0	20	10

Table 1. Recombinant proteins and hyperacute rejection of mouse heart grafts in Gal mice^a Recombinant proteins were injected 10 minutes prior to serum injection, at a dose of 4.5 nM.^b Hyperacute rejection of Gal+ mouse hearts was induced by the injection of fresh human serum into the Gal/o recipient mouse. Rejection was scored as the cessation of coordinated myocardial contraction, concurrent with swelling and darkening of the heart graft. Hearts not rejected within the 90-min observation period are indicated.




Figure 8. Histology of transplanted mouse hearts showing hyperacute graft rejection or protection by chimeric protein. Hematoxylin and eosin-stained sections x20. Transplanted hearts were taken after complete hyperacute rejection had occurred (defined by cessation of contractions) after injection of human serum (A) or when still functioning 90 min after the separate injections of human serum and a single preceding 4.5 nM dose of rsFcR:CD46 (B) or rsCD46 (C).

DISCUSSION

In this study we report the design and production of two novel recombinant soluble chimeric proteins that combine the functional domains of the complement regulator CD46 and the human IgG-binding low affinity Fc receptor (FcγRII). Previously, we had studied the effects of recombinant soluble CD46 (rsCD46) and rsFcγRII alone in the reverse passive Arthus reaction, and noted that although they were each highly inhibitory [at maximal doses of 70 µg for rsCD46 (3) and 500 µg for rsFcγRII (9)], they were unable to entirely block the inflammation. Similarly, rsCD46 delayed hyperacute graft rejection in a rodent model, reducing the early deposition of complement but not preventing organ destruction (3). It was possible that both rsCD46 and rsFcγRII together would be more efficient, and that combining the two functional domains in a novel protein might result in enhanced antiinflammatory function. First, Ig-binding properties could serve to concentrate such proteins on surfaces coated with immunoglobulin or immune complexes. Second, the positioning of a complement regulatory domain close to an immunoglobulin molecule could enhance its ability to regulate the classical pathway, which is activated by antibody. Third, an increase in the molecular weight afforded by the addition of functional modules could result in an increase in a longer half-life (a known limitation of proteins <60 kDa; the molecular weight of rsFcγRII is 25 kDa and of rsCD46 is 55 kDa).

The two chimeric proteins, with alternate positioning of the components, were shown to conserve conformation-dependent epitopes and to possess the functional attributes of rsCD46 and rsFcγRII. Both chimeric proteins functioned similarly *in vitro*; there were no obvious effects resulting from the different orientations of the functional domains or from steric effects of adjacent modules. The dose-effect curves presented here for protection of CHO-K1 cells from lysis by rsCD46 (Fig. 4B) closely paralleled those of a

previous study in which 1-2 μ M concentrations were found to be effective (16).

The chimeric proteins retained the *in vivo* ability of both parent molecules to inhibit the reverse passive Arthus reaction in rats. The demonstration by microscopy of a markedly reduced cellular infiltrate (PMN <10% of maximum) was a more sensitive indicator of antiinflammatory activity than the reduction of edema as determined by dye leakage. No added inhibition was seen for the chimeric molecules, or for mixtures of both parent molecules; this suggests that either higher concentrations of the inhibitors are needed, or that inflammatory processes additional to complement activation and Fc receptor interactions are involved.

The development of experimental model systems to study hyperacute organ graft rejection, as occurs for discordant xenografts such as pig organs into humans, can be complicated. The recent production of mice in which the α 1,3 galactosyl transferase gene has been inactivated by homologous recombination (Gal o/o) (18) has provided a more elegant system and one closer to xenograft combinations likely to be used clinically. Heart allografts transplanted from normal (Gal+) inbred mice to the abdominal cavity of Gal o/o recipients are rejected in about a week by cell-mediated responses, unless the recipients are hyperimmunized and have a high titer of anti-Gal antibodies, or anti-Gal antibody plus complement (e.g., fresh human serum) is injected; then hyperacute rejection occurs, with fibrillation and bruising evident within 10 to 15 min, leading to thrombosis, engorgement of the graft, and rapid loss of myocardial contraction (1).

The chimeric molecule rsFcR:CD46 prevented hyperacute heart graft rejection more reliably than equivalent molar amounts of rsCD46 ($P < 0.05$). This process is predominantly mediated by naturally occurring anti-Gal IgM antibodies in human serum, although deposition of IgG antibodies (which are not capable of causing HAR alone) also occurs (1). The observation that soluble forms of FcyRII did not influence the process is to be expected. The enhanced activity of rsFcR:CD46 over rsCD46 suggested that the FcyRII domain may be providing a useful function, possibly by allowing the bifunctional protein to localize to the areas of immunoglobulin deposition, or through contribution to protein size. The circulating half-life in mice of rsFcR:CD46 (alpha-phase 1.3 min, with an extended beta-phase), which is more than that of rsCD46 (alpha-phase <1 min) (3), may explain its increased efficacy. In support of this explanation, another recombinant construct with an increased molecular weight, rsCD46:EGFP, was also better able to inhibit HAR in the mouse model than rsCD46. However, the ability of FcR:CD46 to prevent much of the macroscopic and histological evidence of tissue damage, which was still apparent in animals treated with rsCD46:EGFP, suggests that the addition of an FcyRII domain may be useful apart from any increase in half-life.

The *in vivo* rodent models of inflammation and disease are convenient experimental models to establish principles of function; however, they can suffer from limitations due to different molecular functions between species. FcyRII binds mouse IgG similarly to human IgG, but CD46 functions, involving binding of C3b or C4b and an interaction with the serum protease factor I, appear to be less efficient with rodent serum. We had previously studied the ability of CD46 to inhibit mouse spleen cell lysis mediated by rat complement *in vitro* and found that it controlled complement activation through the alternative pathway (although not as efficiently as with human complement), but protection against the classical pathway was poor (13). In both *in vivo* models used in our study, the classical pathway would be expected to play a principal role in inflammation. Thus, the reverse passive Arthus results, involving only rodent complement, probably underestimate the ability of CD46 domains to function in a human clinical setting. In the mouse heart graft model, human serum was injected to precipitate graft rejection. As the relevant human anti-Gal antibodies would be focused almost entirely on the graft tissue in the Gal o/o mice, and the circulating human complement components would tend to be activated at this site, this model provides good evidence of highly effective protection mediated by CD46. These data showed a greater protective effect of CD46 than earlier rodent xenotransplant studies in which the hyperacute rejection of mouse hearts in rats was initiated by immune rat serum (3, 13).

The organs of transgenic animals expressing cell-surface complement regulators (CD46, CD55, and CD59) have been shown to be protected against hyperacute rejection in many studies (2, 13). Soluble CR1 (sCR1) has also been shown to delay hyperacute rejection in small animal models (27) and the pig to primate combination (28). Doses of 15 mg/kg were used to achieve inhibition; the dose of rsCD46 used in this study was 8 mg/kg, although the dose of FcR:CD46 was 13 mg/kg. Inhibition of the reverse passive Arthus reaction in rodents has been demonstrated for several other soluble complement regulators as well as rsCD46; sCR1 (29), soluble CD55 (seDAF) (30), and CAB-2, a soluble complement regulator combining CD46 and CD55 domains (31). All were capable of $\leq 50\%$ reduction in edema at intradermal doses ranging

from 10 µg (sCR1) to 100 µg (seDAF). Mast cell degranulation (32) and white blood cell activation through Fc receptors are probably responsible for generation of the remaining edema.

The ability of the CD46/FcR recombinant chimeric proteins to control complement or immune-complex mediated inflammation and hyperacute graft rejection has been clearly demonstrated and we conclude that they have a therapeutic potential, especially where alternative pathway complement activation occurs, and may be superior to soluble complement regulators lacking Fcγ receptor activity. Furthermore, having demonstrated the principle of function, it should not be difficult to add FcγRII domains to other soluble complement regulators, including those able to regulate the antibody-mediated classical activation pathway through other mechanisms (such as CD35 or CD55). This approach may offer a way of improving the antiinflammatory activity of soluble complement regulators in antibody-mediated disease.

REFERENCES TOP

1. McKenzie IFC, Li YQ, Patton K, Thall AD, Sandrin MS. A murine model of antibody-mediated hyperacute rejection by galactose-α(1-3)galactose antibodies in Gal o/o mice. *Transplantation* 1998; 66 (6):754.
[Fulltext Link] [CrossRef] [Context Link]
2. Kirschnick M. Controlling the complement system in inflammation. *Immunopharmacology* 1997; 38:51.
[CrossRef] [Context Link]
3. Christiansen D, Milland J, Thorley BR, McKenzie IFC, Loveland BE. A functional analysis of recombinant soluble CD46 *in vivo* and a comparison with recombinant soluble forms of CD55 and CD35 *in vitro*. *Eur J Immunol* 1996; 26:578.
[Context Link]
4. Deo YM, Graziano, RF, Repp R, van de Winkel JGJ. Clinical significance of IgG Fc receptors and FcR-directed immunotherapies. *Immunology Today* 1997; 18:127.
[CrossRef] [Context Link]
5. Gavin AL, Snider J, Hulett MD, McKenzie IFC, Hogarth PM. Expression of recombinant soluble Fc epsilon RI: function and tissue distribution studies. *Immunology* 1995; 86:392.
[Context Link]
6. Sylvestre DL, Ravetch JV. Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. *Science* 1994; 265:1095.
[Context Link]
7. Glynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. *Science* 1998; 279:1052.
[Context Link]
8. Teillaud JL, Bouchard C, Astier A, et al. Natural and recombinant soluble low-affinity Fc gamma R: detection, purification, and functional activities. *Immunomethods* 1994; 4:48.
[Medline Link] [CrossRef] [Context Link]
9. Ierino FL, Powell MS, McKenzie IFC, Hogarth PM. Recombinant soluble human Fc gamma RII: production, characterization, and inhibition of the Arthus reaction. *J Exp Med* 1993; 178:1617.
[CrossRef] [Context Link]
10. Kojima A, Iwata K, Seya T, et al. Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis. *J Immunol* 1993; 151:1519.
[Context Link]
11. Loveland BE, Johnstone RW, Russell SM, Thorley B, McKenzie IFC. Different Membrane Cofactor Protein (CD46) isoforms protect transfected cells against antibody and complement mediated lysis. *Transplant Immunol* 1993; 1:101.
[Medline Link] [CrossRef] [Context Link]
12. Oglesby TJ, Allen CJ, Liszewski MK, White DJ, Atkinson JP. Membrane cofactor protein (CD46) protects cells from complement-mediated attack by an intrinsic mechanism. *J Exp Med* 1992; 175:1547.
[CrossRef] [Context Link]
13. Thorley BR, Milland J, Christiansen D, et al. Transgenic expression of a CD46 (membrane cofactor protein) minigene: studies of xenotransplantation and measles virus infection. *Eur J Immunol* 1997;

27:726.

[\[Context Link\]](#)

14. Mulder LCF, Mora M, Ciccopiedi E, et al. Mice transgenic for human CD46 and CD55 are protected from human complement attack. *Transplant Proc* 1995; 27:333.

[\[Context Link\]](#)

15. Yannoutsos N, Ijzermans JNM, Harkes C, et al. A membrane cofactor protein transgenic mouse model for the study of discordant xenograft rejection. *Genes Cells* 1996; 1:409.

[\[Context Link\]](#)

16. Christiansen D, Milland J, Thorley BR, et al. Engineering of recombinant soluble CD46: an inhibitor of complement activation. *Immunology* 1996; 87:348.

[\[Fulltext Link\]](#) [\[Context Link\]](#)

17. Hulett MD, Hogarth PM. Molecular basis of Fc receptor function. *Adv Immunol* 1994; 57:1.

[\[Medline Link\]](#) [\[Context Link\]](#)

18. Thall AD, Maly P, Lowe JB. Oocyte Galα1,3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse. *J Biol Chem* 1995; 270:21437.

[\[CrossRef\]](#) [\[Context Link\]](#)

19. Sparrow RL, McKenzie IFC. HuLy-m5: a unique antigen physically associated with HLA molecules. *Hum Immunol* 1993; 7:1.

[\[Medline Link\]](#) [\[CrossRef\]](#) [\[Context Link\]](#)

20. Seya T, Hara T, Uenaka A, Nakayama E, Akedo H. Application of protein A-rosette assay for screening of monoclonal antibodies to human complement regulatory proteins. *Complement Inflamm* 1990; 7:78.

[\[Context Link\]](#)

21. Ierino FL, Powell MS, McKenzie IFC, Hogarth PM. Functional recombinant soluble human Fc gamma RII. *Transplant Proc* 1992; 24:2326.

[\[Medline Link\]](#) [\[Context Link\]](#)

22. Evans MJ, Hartman SL, Wolff DW, Rollins SA, Squinto SP. Rapid expression of an anti-human C5 chimeric Fab utilizing a vector that replicates in COS and 293 cells. *J Immunol Methods* 1995; 184:123.

[\[CrossRef\]](#) [\[Context Link\]](#)

23. Purcell DFJ, Russell SM, Deacon NJ, Brown MA, Hooker DJ, McKenzie IFC. Alternatively spliced mRNA's encode several isoforms of CD46 (MCP), a regulator of complement activation. *Immunogenetics* 1991; 33:335.

[\[Context Link\]](#)

24. Hibbs ML, Classon BJ, Walker ID, McKenzie IFC, Hogarth PM. The structure of the murine Fc receptor for IgG. Assignment of intrachain disulfide bonds, identification of N-linked glycosylation sites, and evidence for a fourth form of Fc receptor. *J Immunol* 1988; 140:544.

[\[Medline Link\]](#) [\[Context Link\]](#)

25. Cormack BP, Valdivia RH, Falkow S. FACS-optimized mutants of the green fluorescent protein (GFP). *Gene* 1996; 173:33.

[\[CrossRef\]](#) [\[Context Link\]](#)

26. Gill SC, von Hippel PH. Calculation of protein extinction coefficients from amino acid sequence data. *Anal Biochem* 1989; 182:319.

[\[Context Link\]](#)

27. Pruitt SK, Baldwin 3rd WM, Marsh Jr HC, Lin SS, Yeh CG, Bollinger RR. The effect of soluble complement receptor type 1 on hyperacute xenograft rejection. *Transplantation* 1991; 52:868.

[\[Medline Link\]](#) [\[Context Link\]](#)

28. Pruitt SK, Bollinger RR, Collins BH, et al. Effect of continuous complement inhibition using soluble complement receptor type 1 on survival of pig-to-primate cardiac xenografts. *Transplantation* 1997; 63:900.

[\[Fulltext Link\]](#) [\[CrossRef\]](#) [\[Context Link\]](#)

29. Yeh CG, Marsh HC Jr, Carson GR, et al. Recombinant soluble human complement receptor type 1 inhibits inflammation in the reverse passive arthus reaction in rats. *J Immunol* 1991; 146:250.

[\[Medline Link\]](#) [\[Context Link\]](#)

30. Moran P, Besley H, Gorrell A, et al. Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo. *J Immunol* 1992; 149:1736.

[\[Medline Link\]](#) [\[Context Link\]](#)

31. Higgins PJ, Ko JL, Lobell R, Sardonini C, Alessi MK, Yeh CG. A soluble chimeric complement inhibitory protein that possesses both decay-accelerating and factor I cofactor activities. *J Immunol* 1997; 158:2872.

[Context Link]

32. Sylvestre DL, Ravetch JV. A dominant role for mast cell Fc receptors in the Arthus reaction. *Immunity* 1996; 5:387.

[CrossRef] [Context Link]

© 2000 Lippincott Williams & Wilkins, Inc.

Copyright © 2006, Lippincott Williams & Wilkins. All rights reserved.

Published by Lippincott Williams & Wilkins.

[Copyright/Disclaimer Notice](#) • [Privacy Policy](#)

 [Subscribe to RSS feed](#)

Ulrichspt61

Release 4.6.1